• Precision Peptide signed an agreement with a U.S. telehealth prescribing and infrastructure partner to support prescription access to its peptide products.
• Deal adds compliant prescribing, pharmacy fulfillment, and delivery workflows across all 50 states via a platform used by more than 100 telehealth brands.
• Partnership builds on a June 2, 2026 503A compounding agreement to produce the company’s peptides, including BPC-157, entirely in the U.S.
• Infrastructure positions the company ahead of the FDA PCAC review of BPC-157 and other peptides scheduled for July 23, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606090730NEWSFILECNPR____20260609_300637_1) on June 09, 2026, and is solely responsible for the information contained therein.